ISI Group Initiates Coverage of LabCorp, Quest at Neutral | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm International Strategy & Investment Group today initiated coverage of clinical laboratories Laboratory Corporation of America and Quest Diagnostics with Neutral ratings on their stock.

ISI put a price target of $110.50 on LabCorp shares and a price target of $63.00 on Quest's stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.